DXB

0.00%

37.5¢ dimerix limited

Great points mate. Seems there will a hint of efficacy though,...

First 201 Last

Share
Profile

Follow
oilandgasman

1,344 Posts.

102

08/07/17

23:28

Post #: 25749729
Share

Originally posted by Ahmed ↑

Thanks for sharing Prestonian..

1. Agree some ex-Sun Biomedical holders may have sold out since the RTO. The largest SBN holder was Jason Peterson and he recently has sold down his entire holding- which has added to significant supply in recent times.. This is now done.

2. Agree in part that the fact that safety and efficacy hasn't been definitively been demonstrated , given this is the first clinical study, has limited the share price. However, we should keep a few things in mind here- the two compounds are registered and approved drugs! No need to show safety as individual drugs in the dosages used.. This is a huge advantage- better than any other new drug that has shown safety in ph2 or even ph3 trials. The combo mechanistically should be safe, but agree this needs to be shown. Having said that, in my experience the ASX biotech punters don't pay much of a premium for showing safety.. They only want to see efficacy. Also- pls note you won't see any real efficacy in Ph1 studies.

If you look at ACW - it has a market cap of closer to $40M with only phase 1 safety data.. Ph2a just started.. Innate was buoyed by encouraging outcomes with their NZ patients obtaining the drug under compassionate access schemes and positive messaging from the Compamy throughout the study , but that obviously didn't turn out well. PBT really only had safety demonstrated before its ph2b bombed.. Not before a huge rise in the stock price. And then there's little old DXB.. Got a great basis to be safe, has shown in a small sample of 11 patients that it can be extremely effective treating proteinuria in some patients already.. So one would expect it to be trading higher than it is..

So why is the price so low relative to others.. Who knows , maybe..

SBN overhang. Ridiculously low CR at 0.6c in Jan has limited the recent SP gains. Limited broker support. No institutional support (too much for most instos, but wouldn't mind an AEF on board), Lack of strong East Coast support base and awareness. Technology is too complex for most and has until recently been poorly communicated by management. Market value proposition with DMx-200 and CKD /FSGS has been undersold. Business model undersold (licensing opportunities). Overly scientific and conservative approach in communications from the Company to date- much improved now. Other than James Williams- unknown Board. Hugh helps. A decent scientific advisory Board would help too.

Seems like a lot of the above are either being proactively fixed by the Company or are naturally resolving.. So with upcoming results, greater awareness, higher profile board and better corporate messaging- it seems the fun will start after the results rather than before as has been the case with a number of its peers..

All the best guys.. Whatever your strategy is with DXB!

A.

Expand

Great points mate.

Seems there will a hint of efficacy though, given there was with the first set of results.

Why don't instos invest?

DXB Price at posting: 1.1¢ Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

TYX

Tyranna wraps up lithium drilling in Angola; says looking for other projects with different metals

GDM

Banshee's historic trenches prove rich in antimony and gold for GDM

CLE

Cyclone signs MOU with Vale for development of Iron Bear play

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

EEG

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

BNL

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

CUF

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

IRX

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

3DA

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

First 201 Last

Add DXB (ASX) to my watchlist

(20min delay)
Last 37.5¢		Change 0.000(0.00%)		Mkt cap ! $209.1M

Open	High	Low	Value	Volume
38.0¢	38.5¢	36.5¢	$579.4K	1.548M

Buyers (Bids)

No.	Vol.	Price($)
1	91570	37.0¢

Sellers (Offers)

Price($)	Vol.	No.
37.5¢	7922	2

View Market Depth

No.	Vol.	Price($)
1	91570	0.370
10	171185	0.365
13	301942	0.360
3	73000	0.355
9	211495	0.350

Price($)	Vol.	No.
0.375	7922	2
0.380	72644	5
0.390	17637	3
0.395	142800	4
0.400	277640	8

Last trade - 16.10pm 15/11/2024 (20 minute delay)

DXB (ASX) Chart

Great points mate. Seems there will a hint of efficacy though,...

Tyranna wraps up lithium drilling in Angola; says looking for other projects with different metals

Banshee's historic trenches prove rich in antimony and gold for GDM

Cyclone signs MOU with Vale for development of Iron Bear play

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Great points mate. Seems there will a hint of efficacy though,...

Top Stories

Tyranna wraps up lithium drilling in Angola; says looking for other projects with different metals

Banshee's historic trenches prove rich in antimony and gold for GDM

Cyclone signs MOU with Vale for development of Iron Bear play

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News